SAN DIEGO, Nov. 8, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at three investor conferences November 13 - 15. These three corporate presentations will be webcast.
Tuesday, November 13th at 1:30 p.m. Eastern Time: Lazard Capital Markets 9th Annual Healthcare Conference in New York City
Thursday, November 15 th at 3 p.m. Greenwich Mean Time: Jefferies 2012 Global Healthcare Conference in London
Thursday, November 15th at 1:30 p.m. Mountain Time: Credit Suisse Healthcare Conference in Phoenix
To listen to the live webcast or a replay of the presentations, please visit the Investor Relations section of the Company’s Web site at www.orexigen.com. A replay will be available for 14 days after each event.
About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company’s lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company’s other product candidate, Empatic, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com.
Orexigen Contact: | Media Contact: |
McDavid Stilwell | Denise Powell |
VP, Corporate Communications and Business Development | WCG |
(858) 875-8629 | (510) 703-9491 |
SOURCE Orexigen Therapeutics, Inc.
